Table 2.

Base case cost, effect and cost-effectiveness results

Patient cohort	Alternative	QALY	Difference	WDL	Difference	Costs	Difference	ICER1	NB1	ICER2	NB2
Mild depression	ETB	0.7235	0.0008	2.8326	−0.0456	287.57	8.87	10 531	16	4092	22
	No ETB	0.7226		2.8782		278.70
Moderate depression	ETB	0.6742	0.0021	8.0341	−0.1675	320.69	9.99	4661	54	ETB dom	74
	No ETB	0.6721		8.2016		310.70
Severe depression	ETB	0.5769	0.0046	34.1694	−0.7836	394.83	12.03	2596	127	ETB dom	220
	No ETB	0.5723		34.9531		382.80
New diagnosis	ETB	0.6693	0.0023	11.8236	−0.2570	325.76	10.06	4463	58	ETB dom	88
	No ETB	0.6671		12.0806		315.70
Recurrent episode	ETB	0.6640	0.0024	12.9020	−0.2824	329.62	10.18	4254	62	ETB dom	95
	No ETB	0.6616		13.1844		319.44
Overall	ETB	0.6667	0.0023	12.3628	−0.2697	327.69
	No ETB	0.6644		12.6325		317.57	10.12	4355	60	ETB dom	92

ETB dom, ETB dominates the ‘no ETB’ alternative; ETB, P1vital Oxford Emotional Test Battery; ICER1, incremental cost-effectiveness ratio from the healthcare’s perspective; ICER2, incremental cost-effectiveness ratio from the societal perspective; NB1, net benefit from the healthcare’s perspective; NB2, net benefit from the societal perspective;QALY, quality-adjusted life year; WDL, work days lost.